Results 11 to 20 of about 48,812 (228)

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. [PDF]

PLoS ONE, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Carola Berking, Tanja Bergmann, Clemens L Bockmeyer, Thomas Eigentler, Michael Fluck, Claus Garbe, Ralf Gutzmer, Stephan Grabbe, Axel Hauschild, Rüdiger Hein, Gheorghe Hundorfean, Armin Justich, Ullrich Keller, Christina Klein, Christine Mateus, Peter Mohr, Sylvie Paetzold, Imke Satzger, Dirk Schadendorf, Marc Schlaeppi, Gerold Schuler, Beatrice Schuler-Thurner, Uwe Trefzer, Jens Ulrich, Julia Vaubel, Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie M Heinzerling   +35 more
doaj   +3 more sources

Ipilimumab [PDF]

Reactions Weekly, 2019
En definitiva, el desarrollo del ipilimumab, el primer anticuerpo contra un punto de control inmunológico, ha demostrado su eficacia en el control de diversos tumores malignos, ha iniciado el renacer de la inmunooncología que está revolucionando el ...
Jantus-Lewintre, Eloisa, Sirera Pérez, Rafael   +1 more
core   +4 more sources

Ipilimumab-Induced Neutropenia in Melanoma

Journal of Investigative Medicine High Impact Case Reports, 2016
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related.
Makiko Ban-Hoefen MD, Richard Burack MD, Lynn Sievert NP, Deepak Sahasrabudhe MD   +3 more
doaj   +2 more sources

Ipilimumab in melanoma

Expert Review of Anticancer Therapy, 2012
: Ipilimumab is a fully human monoclonal antibody directed against the cytotoxic T-lymphocyte antigen-4 receptor. Blocking cytotoxic T-lymphocyte antigen-4 signaling has been shown to enhance T-cell activation and to amplify T-cell-mediated immunity ...
Specenier, Pol
core   +7 more sources

Ipilimumab-Induced Enteritis without Colitis: A New Challenge

Case Reports in Oncology, 2016
Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma.
Marcus Messmer, Sunita Upreti, Yaman Tarabishy, Nikhilesh Mazumder, Reezwana Chowdhury, Mark Yarchoan, Matthias Holdhoff   +6 more
doaj   +2 more sources

Ipilimumab: its potential in non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2012
Ipilimumab is a fully human monoclonal antibody that enhances antitumor immunity by way of cytotoxic T-lymphocyte antigen 4 blockade. It has already been approved by the US Food and Drug Administration for the treatment of metastatic melanoma and is ...
Pascale Tomasini, Nataliya Khobta, Laurent Greillier, Fabrice Barlesi   +3 more
doaj   +2 more sources

Profile of ipilimumab and its role in the treatment of metastatic melanoma

Drug Design, Development and Therapy, 2011
Sapna P Patel, Scott E WoodmanMelanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USAAbstract: Melanoma is an immunogenic cancer.
Patel SP, Woodman SE
doaj   +1 more source

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. [PDF]

, 2022
PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
Dummer, R, Daniels, GA, Ferrucci, PF, Hodi, FS, Bas, T, Ascierto, PA, Schadendorf, D, Ritchings, C, Wolchok, JD, Schöffski, P, Grob, JJ, Wagstaff, J, Cowey, CL, Haanen, JBAG, Hill, A, Long, GV, Lao, CD, Gonzalez, R, Lebbé, C, Rutkowski, P, Smylie, M, Carlino, MS, Guidoboni, M, Larkin, J, Márquez-Rodas, I, Butler, MO, McArthur, G, Grob, J-J, Chiarion-Sileni, V, Maio, M   +29 more
core   +4 more sources

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma [PDF]

New England Journal of Medicine, 2015
In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment,
Michael A, Postow, Jason, Chesney, Anna C, Pavlick, Caroline, Robert, Kenneth, Grossmann, David, McDermott, Gerald P, Linette, Nicolas, Meyer, Jeffrey K, Giguere, Sanjiv S, Agarwala, Montaser, Shaheen, Marc S, Ernstoff, David, Minor, April K, Salama, Matthew, Taylor, Patrick A, Ott, Linda M, Rollin, Christine, Horak, Paul, Gagnier, Jedd D, Wolchok, F Stephen, Hodi   +20 more
openaire   +2 more sources

Ipilimumab [PDF]

Drugs in R&D, 2010
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II ...
openaire   +2 more sources